Rosen reminds Embecta investors of Aug. 17, 2026 class action deadline
Investors who bought Embecta common stock between Nov. 25, 2025 and May 4, 2026 may seek lead plaintiff status in a suit alleging misleading fiscal guidance and disclosures about its pen needle business.
Rosen Law Firm is reminding investors who purchased Embecta Corp. common stock between November 25, 2025 and May 4, 2026 that they have until August 17, 2026 to seek appointment as lead plaintiff in a securities class action. The lawsuit alleges Embecta made false or misleading statements, or concealed material adverse facts, about its fiscal results and knew or recklessly disregarded that its guidance was misleading and unattainable. The complaint says Embecta described its pen needle business as "incredibly resolute" weeks before missing expectations and cutting fiscal 2026 guidance. Investors who do not seek lead plaintiff status may still share in any future recovery if the litigation succeeds.
- lead plaintiff: The investor appointed by the court to represent the proposed class and help direct the litigation.
- securities class action: A lawsuit in which investors allege they were harmed by misleading statements or omissions affecting a company's securities.